This MedLibrary.org supplementary page on Levosimendan is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Levosimendan
|
|
| Systematic (IUPAC) name | |
| (-)-(R)-(4-(4-methyl-6-oxo- 1,4,5,6-tetrahydropyridazin-3-yl)phenyl) carbonohydrazonoyl dicyanide |
|
| Identifiers | |
| CAS number | |
| ATC code | C01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C14H12N6O |
| Mol. mass | 280.28 |
| Pharmacokinetic data | |
| Bioavailability | 85% (oral) |
| Metabolism | hepatic |
| Half life | 1 hour |
| Excretion | renal |
| Therapeutic considerations | |
| Pregnancy cat. |
no data |
| Legal status |
Prescription only. Not marketed in the U.S. |
| Routes | IV |
Levosimendan (INN) (pronounced /ˌliːvoʊsaɪˈmɛndən/) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. It is marketed under the trade name Simdax (Abbott).
Contents |
Mode of action
Levosimendan is a calcium sensitiser – it increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan exerts its positive inotropic effect by increasing calcium sensitivity of myocytes by binding to cardiac troponin C in a calcium-dependent manner. It also has a vasodilatory effect, by opening adenosine triphosphate (ATP)-sensitive potassium channels in vascular smooth muscle to cause smooth muscle relaxation. The combined inotropic and vasodilatory actions result in an increased force of contraction, decreased preload and decreased afterload. Moreover, by opening also the mitochondrial (ATP)-sensitive potassium channels in cardiomyocytes, the drug exerts a cardioprotective effect.
Clinical use
Indications
Levosimendan is indicated for inotropic support in acutely-decompensated severe congestive heart failure.
Some of the Phase-III studies in the extensive clinical program were the trials LIDO (200 patients), RUSSLAN (500), CASINO (250), REVIVE-I (100), REVIVE-II (600) and finally SURVIVE (1350),[1] a head-to-head trial between levosimendan and dobutamine in acute decompensated heart failure. In total, the clinical data base includes more than 3500 patients in Phase IIb and III double-blind studies, which is the highest number ever in testing a drug for acute decompensated heart failure.citation needed
Despite an initial reduction in plasma B-type natriuretic peptide level in patients in the levosimendan group compared with patients in the dobutamine group in a head to head comparison study, levosimendan did not significantly reduce all-cause mortality at 180 days or affect any secondary clinical outcomes.[1]
The drug has a marketing authorization in 48 countries.citation needed
Contraindications
The use of levosimendan is contraindicated in patients with: moderate-to-severe renal impairment, severe hepatic impairment, severe ventricular filling or outflow obstruction, severe hypotension and tachycardia, and/or history of torsades de pointes.[2]
Adverse effects
Common adverse drug reactions (≥1% of patients) associated with levosimendan therapy include: headache, hypotension, arrhythmias (atrial fibrillation, extrasystoles, atrial tachycardia, ventricular tachycardia), myocardial ischaemia, hypokalaemia and/or nausea (Rossi, 2006).
Formulations
Levosimendan is marketed as a 2.5 mg/mL concentrated solution for IV infusion. The concentrate is diluted with glucose 5% solution before infusion.
References
- ^ a b Mebazaa, A; Nieminen MS, Packer M, Cohen-Solal, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M for the SURVIVE investigators (2007). "Levosimendan vs dobutamine for patients with acute decompensated heart failure". JAMA 297 (17): 1883–91. doi:. PMID 17473298.
- ^ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006.
|
||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 22 July 2008, at 08:33.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Levosimendan".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.